Wasn’t hmi-115 phase 1 supposed to end in july? We’ve heard nothing so far
Research/Science 8/7/2023
HMI-115 prolactin DHT cabergoline hypothalamus-pituitary axis endogenous prolactin production follicle dopamine-prolactin axis phase 1 trial phase 2 trial phase 3 trial hair regrowth hair loss androgenic alopecia
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
View this post in the Community →
Similar Community Posts Join
6 / 139 resultscommunity Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community 2-month HMI-115 results from the Chinese trial
HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.
community HMI 115 Phase 2 - Leaked pics from Discord
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community HMI-115 Australian Phase 1 Trial completed?
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
Related Research
6 / 45 resultsresearch The State-of-the-Art in the Management of Androgenetic Alopecia: A Review of New Therapies and Treatment Algorithms
New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
research Topical Application of the Wnt/β-Catenin Activator Methyl Vanillate Increases Hair Count and Hair Mass Index in Women with Androgenetic Alopecia
Methyl vanillate spray increases hair count and hair mass in women with hair loss.
research A Dietary Supplement Improves Age-Related Dermatological Changes: Observational, Anecdotal, Spontaneous Study
The dietary supplement significantly improved skin, nails, and hair in older adults.
research Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss
New treatment reduces hair shedding and increases hair density in women with early hair loss.
research Hypotensive Activity and Toxicology of Constituents from Bombax Ceiba Stem Bark
Bombax ceiba stem bark extracts can lower blood pressure, but high doses can be toxic and lethal.